164 related articles for article (PubMed ID: 25683228)
21. Vitiligo in 2 patients receiving vemurafenib for metastatic melanoma.
Alonso-Castro L; Ríos-Buceta L; Vano-Galvan S; Moreno C; Soria-Rivas A; Jaén P
J Am Acad Dermatol; 2013 Jul; 69(1):e28-9. PubMed ID: 23768302
[No Abstract] [Full Text] [Related]
22. Erythema nodosum-like panniculitis in patients with melanoma treated with vemurafenib.
Sinha R; Edmonds K; Newton-Bishop J; Gore M; Larkin J; Fearfield L
J Clin Oncol; 2013 Jul; 31(19):e320-1. PubMed ID: 23715570
[No Abstract] [Full Text] [Related]
23. Spindle cell squamous cell carcinoma arising from verrucous hyperplasia during BRAF inhibitor therapy for melanoma.
Ziemer M; Pönitzsch I; Simon JC; Schüürmann M
J Dtsch Dermatol Ges; 2015 Apr; 13(4):326-8. PubMed ID: 25761417
[No Abstract] [Full Text] [Related]
24. Long-term outcome of an intravitreal dexamethasone implant for the treatment of noninfectious uveitic macular edema.
Habot-Wilner Z; Sorkin N; Goldenberg D; Loewenstein A; Goldstein M
Ophthalmologica; 2014; 232(2):77-82. PubMed ID: 25012541
[TBL] [Abstract][Full Text] [Related]
25. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
Owen JL; Lopez IE; Desai SR
J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
[TBL] [Abstract][Full Text] [Related]
26. Sarcoidosis in Patients Treated with Vemurafenib for Metastatic Melanoma: A Paradoxical Autoimmune Activation.
Lheure C; Kramkimel N; Franck N; Laurent-Roussel S; Carlotti A; Queant A; Goldwasser F; Avril MF; Dupin N
Dermatology; 2015; 231(4):378-84. PubMed ID: 26452227
[TBL] [Abstract][Full Text] [Related]
27. BRAF inhibitors-induced panniculitis: a cutaneous side effect mimicking subcutaneous melanoma metastasis.
Chaminade A; Conte H; Jouary T; Fauconneau A; Darrigade AS; Beylot-Barry M; Pham-Ledard A
J Eur Acad Dermatol Venereol; 2015 Feb; 29(2):392-393. PubMed ID: 24533578
[No Abstract] [Full Text] [Related]
28. Early treatment response of fluocinolone (retisert) implantation in patients with uveitic macular edema: an optical coherence tomography study.
Shen BY; Punjabi OS; Lowder CY; Sears JE; Singh RP
Retina; 2013 Apr; 33(4):873-7. PubMed ID: 23407350
[TBL] [Abstract][Full Text] [Related]
29. Intravitreal triamcinalone acetonide for refractory uveitic cystoid macular oedema: longterm management and outcome.
Angunawela RI; Heatley CJ; Williamson TH; Spalton DJ; Graham EM; Antcliffe RJ; Stanford MR
Acta Ophthalmol Scand; 2005 Oct; 83(5):595-9. PubMed ID: 16187999
[TBL] [Abstract][Full Text] [Related]
30. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
31. Dexamethasone implant in pediatric uveitis.
Taylor SR; Tomkins-Netzer O; Joshi L; Morarji J; McLoone E; Lightman S
Ophthalmology; 2012 Nov; 119(11):2412-2412.e2. PubMed ID: 23122465
[No Abstract] [Full Text] [Related]
32. Vemurafenib. Value unclear in metastatic melanoma.
Prescrire Int; 2012 Dec; 21(133):288-90. PubMed ID: 23373092
[TBL] [Abstract][Full Text] [Related]
33. Intravitreal triamcinolone acetonide for treatment of cystoid macular edema associated with retinitis pigmentosa.
Kim JE
Retina; 2006; 26(9):1094-6. PubMed ID: 17151506
[No Abstract] [Full Text] [Related]
34. Intravitreal triamcinolone in two patients with refractory macular oedema in sarcoid uveitis.
Larsson J; Hvarfner C; Skarin A
Acta Ophthalmol Scand; 2005 Oct; 83(5):618-9. PubMed ID: 16188004
[No Abstract] [Full Text] [Related]
35. Regression of orbital and choroidal metastases from melanoma after treatment with vemurafenib.
Ngo E; Hutchins LF; Gardner JM; Uwaydat SH
Can J Ophthalmol; 2014 Apr; 49(2):e49-52. PubMed ID: 24767240
[No Abstract] [Full Text] [Related]
36. [Safety and efficacy of subconjunctival triamcinolone injections in the management of uveitic macular edema: retrospective study of thirty-one cases].
Bleriot A; Couret C; Le Meur G; Lebranchu P; Weber M
J Fr Ophtalmol; 2014 Oct; 37(8):599-604. PubMed ID: 25199486
[TBL] [Abstract][Full Text] [Related]
37. Intravitreal triamcinolone for macular oedema: efficacy in relation to aetiology.
Sørensen TL; Haamann P; Villumsen J; Larsen M
Acta Ophthalmol Scand; 2005 Feb; 83(1):67-70. PubMed ID: 15715560
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of intravitreal bevacizumab compared with intravitreal and posterior sub-tenon triamcinolone acetonide for treatment of uveitic cystoid macular edema.
Bae JH; Lee CS; Lee SC
Retina; 2011 Jan; 31(1):111-8. PubMed ID: 20856170
[TBL] [Abstract][Full Text] [Related]
39. The BRAF Inhibitor Vemurafenib Enhances UV-Induced Skin Carcinogenesis in Beta HPV38 E6 and E7 Transgenic Mice.
Viarisio D; Müller-Decker K; Hassel JC; Alvarez JC; Flechtenmacher C; Pawlita M; Gissmann L; Tommasino M
J Invest Dermatol; 2017 Jan; 137(1):261-264. PubMed ID: 27650607
[No Abstract] [Full Text] [Related]
40. A case of occipital neuralgia in a vemurafenib-treated melanoma patient.
Hoashi T; Matsumoto N; Serizawa N; Kataoka K; Nako T; Shirakawa N; Matano Y; Funasaka Y; Saeki H
Int J Dermatol; 2017 Jan; 56(1):e10-e11. PubMed ID: 27653311
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
